EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-SA 4.0

First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant

Esther Bernaldo-de-Quirós iD, Manuela Camino iD, Marta Martínez-Bonet iD, Juan Miguel Gil-Jaurena iD, Nuria Gil iD, Diana Hernández-Flórez iD, Maria Eugenia Fernández-Santos iD, Laura Butragueño iD, I Esmé Dijke iD, Megan K Levings iD, Lori J West iD, Marjorie Pion iD und 1 weitere

Journal of Experimental Medicine · 04.12.2023 · 220 (12)

DOI: 10.1084/jem.20231045 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Experimental Medicine, online erschienen am 31.10.2023. Verfasst von Esther Bernaldo-de-Quirós und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immune-Regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain. Hauptthemen laut MEDLINE: Heart Transplantation, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Fundación Familia Alonso, Instituto de Salud Carlos III, Comunidad de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to their suppressive capacity, regulatory T cells (Tregs) have attracted growing interest as an adoptive cellular therapy for the prevention of allograft rejection, but limited Treg recovery and lower quality of adult-derived Tregs could represent an obstacle to success. To address this challenge, we developed a new approach that provides large quantities of Tregs with high purity and excellent features, sourced from thymic tissue routinely removed during pediatric cardiac surgeries (thyTregs). We report on a 2-year follow-up of the first patient treated worldwide with thyTregs, included in a phase I/II clinical trial evaluating the administration of autologous thyTreg in infants undergoing heart transplantation. In addition to observing no adverse effects that could be attributed to thyTreg administration, we report that the Treg frequency in the periphery was preserved during the 2-year follow-up period. These initial results are consistent with the trial objective, which is to confirm safety of the autologous thyTreg administration and its capacity to restore the Treg pool.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationT-Lymphocytes, RegulatoryAdultHumansInfantGraft RejectionTransplantation, Homologous

Autor:innen und Institutionen

  • Laboratory of Immune-Regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain.
  • Department of Pediatric Cardiology, Hospital Gregorio Marañón, Madrid, Spain.
  • Department of Cardiac Pediatric Surgery, Hospital Gregorio Marañón, Madrid, Spain.
  • Cell Production Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Pediatric Intensive Care Unit, Hospital Gregorio Marañón , Madrid, Spain.
  • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

ORCID-Profile: Esther Bernaldo-de-Quirós, Manuela Camino, Marta Martínez-Bonet, Juan Miguel Gil-Jaurena, Nuria Gil, Diana Hernández-Flórez, Maria Eugenia Fernández-Santos, Laura Butragueño, I Esmé Dijke, Megan K Levings, Lori J West, Marjorie Pion, Rafael Correa-Rocha

Förderung

  • Fundación Familia Alonso
  • Instituto de Salud Carlos III
  • Comunidad de Madrid
  • Marie Sklodowska-Curie

Zitieren

APA

Bernaldo-de-Quirós, E., Camino, M., Martínez-Bonet, M., Gil-Jaurena, J. M., Gil, N., Hernández-Flórez, D., Fernández-Santos, M. E., Butragueño, L., Dijke, I. E., Levings, M. K., West, L. J., Pion, M., & Correa-Rocha, R. (2023). First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant. Journal of Experimental Medicine, 220(12). https://doi.org/10.1084/jem.20231045

Vancouver

Bernaldo-de-Quirós E, Camino M, Martínez-Bonet M, Gil-Jaurena JM, Gil N, Hernández-Flórez D, et al. First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant. Journal of Experimental Medicine. 2023;220(12). doi:10.1084/jem.20231045

BibTeX
@article{BernaldodeQuirs2023,
  author = {Bernaldo-de-Quirós, Esther and Camino, Manuela and Martínez-Bonet, Marta and Gil-Jaurena, Juan Miguel and Gil, Nuria and Hernández-Flórez, Diana and Fernández-Santos, Maria Eugenia and Butragueño, Laura and Dijke, I Esmé and Levings, Megan K and West, Lori J and Pion, Marjorie and Correa-Rocha, Rafael},
  title = {First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant},
  journal = {Journal of Experimental Medicine},
  year = {2023},
  volume = {220},
  number = {12},
  doi = {10.1084/jem.20231045}
}
Kostenlos starten →